Literature DB >> 20890737

The status of diagnostic markers for inflammatory bowel disease.

Poonam Beniwal1, Laura Harrell.   

Abstract

Inflammatory bowel disease (IBD), which includes ulcerative colitis, Crohn's disease, and indeterminate colitis, is characterized by chronic inflammation of the digestive tract and has a significant impact on quality of life. Coupled with clinical history, physicians rely on invasive tests (e.g. endoscopy and radiologic examinations) to diagnose IBD. Patients with other gastrointestinal illnesses (e.g. irritable bowel syndrome and celiac disease) may present with symptoms similar to those of an IBD patient. Therefore, a need exists for rapid and noninvasive measures to indicate the presence of IBD. The identification of potential biomarkers associated with IBD has expanded rapidly in the past decade. This article reviews the role of recently studied serologic and fecal markers in the diagnosis of IBD, and differentiation between subtypes of IBD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890737     DOI: 10.1007/s11894-010-0145-9

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  24 in total

1.  Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.

Authors:  Cynthia H Seow; Joanne M Stempak; Wei Xu; Hui Lan; Anne M Griffiths; Gordon R Greenberg; A Hillary Steinhart; Nir Dotan; Mark S Silverberg
Journal:  Am J Gastroenterol       Date:  2009-04-21       Impact factor: 10.864

2.  Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.

Authors:  Iris Dotan; Sigal Fishman; Yaara Dgani; Mikael Schwartz; Amir Karban; Aaron Lerner; Oori Weishauss; Larissa Spector; Avi Shtevi; Rom T Altstock; Nir Dotan; Zamir Halpern
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

3.  [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy].

Authors:  María del Valle García Sánchez; Raúl González; Eva Iglesias Flores; Federico Gómez Camacho; Luis Casais Juanena; Antonio Cerezo Ruiz; Manuel Montero Pérez-Barquero; Jordi Muntané; Juan Francisco de Dios Vega
Journal:  Med Clin (Barc)       Date:  2006-06-10       Impact factor: 1.725

4.  Identification of a novel bacterial sequence associated with Crohn's disease.

Authors:  C L Sutton; J Kim; A Yamane; H Dalwadi; B Wei; C Landers; S R Targan; J Braun
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

5.  Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD.

Authors:  Sari Iltanen; Laura Tervo; Tuula Halttunen; Bo Wei; Jonathan Braun; Immo Rantala; Teemu Honkanen; Mitchell Kronenberg; Hilde Cheroutre; Olga Turovskaya; Ville Autio; Merja Ashorn
Journal:  Inflamm Bowel Dis       Date:  2006-05       Impact factor: 5.325

6.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Authors:  Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

7.  Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Stephan R Vavricka; Lukas E Bruegger; Frank Seibold
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

Review 8.  Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage.

Authors:  D Foell; H Wittkowski; J Roth
Journal:  Gut       Date:  2009-01-09       Impact factor: 23.059

9.  Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.

Authors:  Gil Y Melmed; Phillip R Fleshner; Ovunc Bardakcioglu; Andrew Ippoliti; Eric A Vasiliauskas; Konstantinos A Papadakis; Marla Dubinsky; Carol Landers; Jerome I Rotter; Stephan R Targan
Journal:  Dis Colon Rectum       Date:  2007-12-18       Impact factor: 4.585

10.  The role of fecal calprotectin in investigating inflammatory bowel diseases.

Authors:  Mustafa Erbayrak; Cansel Turkay; Elife Eraslan; Hulya Cetinkaya; Benan Kasapoglu; Mehmet Bektas
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

View more
  5 in total

1.  Late-Onset Crohn's Disease Is A Subgroup Distinct in Genetic and Behavioral Risk Factors With UC-Like Characteristics.

Authors:  Dalin Li; Talin Haritunians; Carol Landers; Alka A Potdar; Shaohong Yang; Hailiang Huang; L Philip Schumm; Mark Daly; Stephan R Targan; Dermot P B McGovern
Journal:  Inflamm Bowel Dis       Date:  2018-10-12       Impact factor: 5.325

2.  Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis.

Authors:  Radha Duttagupta; Sharon DiRienzo; Rong Jiang; Jessica Bowers; Jeremy Gollub; Jessica Kao; Keith Kearney; David Rudolph; Noor B Dawany; Michael K Showe; Tom Stamato; Robert C Getts; Keith W Jones
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

Review 3.  Update on current applications of proteomic in the study of inflammatory bowel disease.

Authors:  Giulia Roda; Alessandra Caponi; Alessandro Sartini; Monica Cevenini; Carolina Colliva; Aldo Roda
Journal:  Ann Gastroenterol       Date:  2012

4.  Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study.

Authors:  João Rovisco; Cátia Duarte; Alberto Batticcioto; Piercarlo Sarzi-Puttini; Antonella Dragresshi; Francisco Portela; Marwin Gutierrez
Journal:  BMC Musculoskelet Disord       Date:  2016-02-16       Impact factor: 2.362

5.  Gastrointestinal disease in Sjogren's syndrome: related to food hypersensitivities.

Authors:  Christine Kim-Lee; Lakshmanan Suresh; Julian L Ambrus
Journal:  Springerplus       Date:  2015-12-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.